PMID- 31353759
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1440-1819 (Electronic)
IS  - 1323-1316 (Linking)
VI  - 73
IP  - 12
DP  - 2019 Dec
TI  - Clinical and brain structural effects of the Illness Management and Recovery 
      program in middle-aged and older patients with schizophrenia.
PG  - 731-737
LID - 10.1111/pcn.12919 [doi]
AB  - AIMS: In this study, we implemented the Illness Management and Recovery (IMR) 
      program for middle-aged and older patients with schizophrenia hospitalized for 
      long periods and assessed the effect of the IMR program on psychiatric symptoms 
      and psychosocial function. The effects of the IMR program on brain structure were 
      also evaluated. METHODS: The IMR program was implemented for 19 patients with 
      schizophrenia; 17 patients with schizophrenia receiving treatment as usual (TAU) 
      were also recruited as controls. In all patients, mean age was 61.4 years (range, 
      50-77 years) and mean hospitalization duration was 13.1 years (range, 1-31 years) 
      at enrollment. Structural magnetic resonance images and Positive and Negative 
      Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF) scores as 
      clinical variables were obtained at the beginning and end of the IMR program. 
      Longitudinal analyses were performed to compare the effects of the IMR program on 
      clinical symptoms and cortical thickness in the superior temporal gyrus (STG) 
      between the IMR and TAU groups. RESULTS: Significant improvements in GAF scores 
      and the total, Insight and Judgment, and Positive components of the PANSS were 
      found in the IMR group compared with the TAU group. Cortical thickness in the 
      left STG was preserved in the IMR group compared with the TAU group. CONCLUSIONS: 
      This is the first report demonstrating the effectiveness of the IMR program for 
      improving psychotic symptoms and psychosocial function and protecting brain 
      structure in middle-aged and older inpatients with schizophrenia hospitalized for 
      long periods.
CI  - (c) 2019 The Authors Psychiatry and Clinical Neurosciences (c) 2019 Japanese Society 
      of Psychiatry and Neurology.
FAU - Nakamura, Ryota
AU  - Nakamura R
AUID- ORCID: 0000-0003-1803-413X
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
AD  - Department of Psychiatry, Yokohama Maioka Hospital, Yokohama, Japan.
FAU - Asami, Takeshi
AU  - Asami T
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
FAU - Yoshimi, Asuka
AU  - Yoshimi A
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
AD  - Department of Psychiatry, Yokohama Maioka Hospital, Yokohama, Japan.
FAU - Kato, Daiji
AU  - Kato D
AD  - Totsuka Nishiguchi Rindou Clinic, Yokohama, Japan.
FAU - Fujita, Emi
AU  - Fujita E
AD  - Division of Clinical Psychology, Yokohama City University Hospital, Yokohama, 
      Japan.
FAU - Takaishi, Masao
AU  - Takaishi M
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
FAU - Yoshida, Haruhisa
AU  - Yoshida H
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
FAU - Yamaguchi, Hiroyuki
AU  - Yamaguchi H
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
FAU - Shiozaki, Kazumasa
AU  - Shiozaki K
AD  - Department of Psychiatry, Yokohama Comprehensive Care Continuum, Yokohama, Japan.
FAU - Kase, Akihiko
AU  - Kase A
AD  - Department of Psychiatry, Yokohama Maioka Hospital, Yokohama, Japan.
FAU - Hirayasu, Yoshio
AU  - Hirayasu Y
AD  - Department of Psychiatry, Graduate School of Medicine, Yokohama City University, 
      Yokohama, Japan.
AD  - Department of Psychiatry, Hirayasu Hospital, Urasoe, Japan.
LA  - eng
GR  - 17K10337/Ministry of Health, Labour and Welfare/
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20190825
PL  - Australia
TA  - Psychiatry Clin Neurosci
JT  - Psychiatry and clinical neurosciences
JID - 9513551
SB  - IM
MH  - Aged
MH  - Atrophy/pathology
MH  - Combined Modality Therapy/*methods
MH  - *Disease Management
MH  - Female
MH  - Humans
MH  - Inpatients/psychology
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neuroimaging
MH  - Program Development
MH  - Schizophrenia/*pathology/*therapy
MH  - *Schizophrenic Psychology
MH  - Temporal Lobe/*pathology
OTO - NOTNLM
OT  - illness management and recovery
OT  - inpatient
OT  - magnetic resonance imaging
OT  - schizophrenia
OT  - superior temporal gyrus
EDAT- 2019/07/30 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/07/30 06:00
PHST- 2018/07/06 00:00 [received]
PHST- 2019/07/17 00:00 [revised]
PHST- 2019/07/23 00:00 [accepted]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/07/30 06:00 [entrez]
AID - 10.1111/pcn.12919 [doi]
PST - ppublish
SO  - Psychiatry Clin Neurosci. 2019 Dec;73(12):731-737. doi: 10.1111/pcn.12919. Epub 
      2019 Aug 25.